Are n-3 fatty acids still cardioprotective?

William Harris

Research output: Contribution to journalArticle

48 Scopus citations

Abstract

Purpose of Review: Several recent randomized trials and subsequent meta-analyses have questioned the value of n-3 fatty acid supplementation in cardiovascular disease risk reduction. Recent Findings: This report focuses on four clinical trials published between 2010 and 2012 that have failed to show benefits of n-3 fatty acids, and on one meta-analysis from 2012 that used a controversial statistical approach in reaching a conclusion of no effect. Summary: The question of the extent to which n-3 fatty acid supplementation reduces risk for cardiovascular disease remains open. Future studies must be properly powered, use doses of n-3 fatty acids significantly higher than those provided in background diets, focus on patient populations with low n-3 fatty acid tissue levels, treat for longer periods of time, and consider the effects of these agents in the great majority of patients who are not on guideline-directed therapeutic regimens. The strong evidence-base from prospective cohort studies and the ever-deepening understanding of the cellular effects of long-chain n-3 fatty acids together support the need for these nutrients in reducing cardiovascular risk. Short-term findings from randomized controlled trials need to be interpreted in the light of all the evidence.

Original languageEnglish (US)
Pages (from-to)141-149
Number of pages9
JournalCurrent Opinion in Clinical Nutrition and Metabolic Care
Volume16
Issue number2
DOIs
Publication statusPublished - Mar 2013
Externally publishedYes

    Fingerprint

Keywords

  • cardiovascular disease
  • meta-analysis
  • n-3 fatty acids
  • randomized trials

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this